GlobeNewswire: Precision Biosciences Contains the last 10 of 64 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T01:31:55ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/04/06/2205041/0/en/Precision-BioSciences-Announces-CEO-Transition-Plan.html?f=22&fvtc=4&fvtv=54047Precision BioSciences Announces CEO Transition Plan2021-04-06T12:35:00Z<![CDATA[Begins Search for Next Chief Executive Officer Begins Search for Next Chief Executive Officer]]>https://www.globenewswire.com/news-release/2021/03/29/2200606/0/en/Precision-BioSciences-to-Participate-in-the-Guggenheim-Healthcare-Talks-2021-Genomic-Medicines-Rare-Disease-Day.html?f=22&fvtc=4&fvtv=54047Precision BioSciences to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day2021-03-29T11:00:00Z<![CDATA[DURHAM, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced it will participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day on April 1, 2021.]]>https://www.globenewswire.com/news-release/2021/03/18/2195283/0/en/Precision-BioSciences-Reports-Fourth-Quarter-and-Fiscal-Year-2020-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=54047Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update2021-03-18T11:00:00Z<![CDATA[Established in vivo genome editing research collaboration and exclusive license agreement with Eli Lilly]]>https://www.globenewswire.com/news-release/2021/03/12/2192008/0/en/Precision-BioSciences-to-Report-Fourth-Quarter-and-Fiscal-Year-2020-Financial-Results-on-March-18-2021.html?f=22&fvtc=4&fvtv=54047Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 20212021-03-12T12:00:00Z<![CDATA[DURHAM, N.C., March 12, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company, today announced it will publish fourth quarter and fiscal year 2020 financial results and provide a business update on Thursday, March 18, 2021.]]>https://www.globenewswire.com/news-release/2021/03/02/2185106/0/en/Precision-BioSciences-to-Present-at-Upcoming-Virtual-Investor-Conferences.html?f=22&fvtc=4&fvtv=54047Precision BioSciences to Present at Upcoming Virtual Investor Conferences2021-03-02T12:00:00Z<![CDATA[DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced management will participate in the following upcoming virtual investor conferences:]]>https://www.globenewswire.com/news-release/2021/02/19/2178792/0/en/Precision-Announces-3-Year-Pre-clinical-Study-Results-Showing-Long-term-Durability-and-Safety-of-ARCUS-In-Vivo-Gene-Editing-to-Cut-LDL-Cholesterol-Levels-in-Nonhuman-Primates.html?f=22&fvtc=4&fvtv=54047Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates2021-02-19T12:00:00Z<![CDATA[Study Led by Gene Therapy Program at the University of Pennsylvania Published in Molecular Therapy Study Led by Gene Therapy Program at the University of Pennsylvania Published in Molecular Therapy]]>https://www.globenewswire.com/news-release/2021/02/04/2169771/0/en/Precision-BioSciences-to-Present-at-Guggenheim-Healthcare-Talks-2021-Oncology-Day.html?f=22&fvtc=4&fvtv=54047Precision BioSciences to Present at Guggenheim Healthcare Talks 2021 Oncology Day2021-02-04T12:00:00Z<![CDATA[DURHAM, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its proprietary ARCUS® genome editing platform, today announced it will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on February 11, 2021 at 2:00 PM ET.]]>https://www.globenewswire.com/news-release/2021/01/25/2163363/0/en/Precision-BioSciences-Receives-Notice-of-Allowance-for-U-S-Patent-Application-Covering-PBCAR19B-a-Stealth-Cell-CD19-Allogeneic-CAR-T-Candidate-for-Non-Hodgkin-Lymphoma.html?f=22&fvtc=4&fvtv=54047Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B, a Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma2021-01-25T12:00:00Z<![CDATA[DURHAM, N.C., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its wholly proprietary ARCUS® genome editing platform, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering PBCAR19B, a next-generation, stealth cell, CD19 product candidate for patients with relapsed/refractory (R/R) Non-Hodgkin Lymphoma (NHL).]]>https://www.globenewswire.com/news-release/2021/01/19/2160447/0/en/Precision-BioSciences-Announces-FDA-Accepts-IND-for-PBCAR19B-a-Next-Generation-Stealth-Cell-CD19-Allogeneic-CAR-T-Candidate-for-Non-Hodgkin-Lymphoma.html?f=22&fvtc=4&fvtv=54047Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma2021-01-19T12:00:00Z<![CDATA[Phase 1 clinical trial of PBCAR19B for patients with relapsed/refractory NHL expected to begin by mid-2021 Phase 1 clinical trial of PBCAR19B for patients with relapsed/refractory NHL expected to begin by mid-2021]]>https://www.globenewswire.com/news-release/2021/01/07/2154789/0/en/Precision-BioSciences-Announces-Closing-of-In-Vivo-Gene-Editing-Collaboration-and-License-Agreement-with-Eli-Lilly-and-Company.html?f=22&fvtc=4&fvtv=54047Precision BioSciences Announces Closing of In Vivo Gene Editing Collaboration and License Agreement with Eli Lilly and Company2021-01-07T12:00:00Z<![CDATA[DURHAM, N.C., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced the closing of its in vivo gene editing research collaboration and exclusive license agreement with Eli Lilly and Company following clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.]]>